KOL Perspectives: Rituximab Use in Lupus

KOL Perspectives: Rituximab Use in Lupus

Summary

This KOL Insight briefing focuses on KOLs views of Rituximab Use in Lupus.

Questions topics -

• Current & future use of RTX in lupus
• Views on RTX’s Phase II/III EXPLORER trial re-analysis
• Opinion on data demonstrating that RTX is effective for the management of refractory SLE
• Views on data from the Phase II SYNBIoSe study assessing RTX + BEL combination therapy
• Lupus patients most suitable for RTX + BEL combination therapy
• Use of RTX + BEL combination therapy

Key Highlights

• Most US KOLs stated that future launch of biosimilar RTX will have no impact on their overall use of RTX, but uptake will depend on price
• Most KOLs highlighted that the level of background medication used in the EXPLORER trial was too high and consequently impeded results
• Most KOLs flagged that payers may be a barrier to combination therapy use, especially given the lack of approval for RTX in lupus.

Scope

• The insight briefing is based on Sociable Pharma’s analysis of primary research with our Lupus key opinion leaders (KOLs).

, we conducted interviews with 10 KOLs -

• 5 Europe-based & 5 N. America-based
• Interviews performed during Q2 2018

KOL data is analyzed to produce -

• Charts summarizing KOL opinions
• Chart call-outs of key information & details
• KOL quotes
• Summary of KOL reporting trends
• Insight from Sociable Pharma's analysts

Reasons to buy

• Combines Qualitative & semi-quantitative insight from key opinion leaders on Rituximab Use in Lupus
• Includes insight & recommendations from our disease-specific healthcare analysts
• Utilizes independent expert viewpoints to validate the impact of new clinical data & emerging trends on management of Lupus
• Provides cost-effective support for your advisory boards, with topics acting as a catalyst for further expert discussion.